What is the role of vigabatrin (Sabril) in the treatment of Lennox-Gastaut syndrome (LGS)?

Updated: Nov 09, 2018
  • Author: Koshi A Cherian, MD; Chief Editor: Amy Kao, MD  more...
  • Print
Answer

Vigabatrin (Sabril) was approved by the US Food and Drug Administration (FDA) in 2009 as monotherapy for infantile spasms in patients 1 month to 2 years old, and as adjunctive therapy for adults with refractory complex partial seizures. In 6 open-label studies involving 78 patients with LGS, 15% became completely seizure free and 44% had a >50% reduction in seizure frequency. [29]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!